Search Results

There are 1339 results for: content related to: Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

  1. Glucagon-like peptide analogues for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Deepson S. Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh and Ailsa Snaith

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD006423.pub2

  2. You have full text access to this OnlineOpen article
    Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Carol H. Wysham, Julio Rosenstock, Marion L. Vetter, Fang Dong, Peter Öhman and Nayyar Iqbal

    Version of Record online : 22 AUG 2017, DOI: 10.1111/dom.13056

  3. Once-Weekly Exenatide: An Extended-Duration Glucagon-Like Peptide Agonist for the Treatment of Type 2 Diabetes Mellitus

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 6, June 2013, Pages: 627–638, Molly G. Minze, Mary S. Klein, Michelle J. Jernigan, Stephen L. Wise and Kristian Frugé

    Version of Record online : 1 APR 2013, DOI: 10.1002/phar.1240

  4. You have full text access to this OnlineOpen article
    Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 75, Issue 4, April 2013, Pages: 979–989, Börje Darpö, Sager Philip, Leigh MacConell, Brenda Cirincione, Malcolm Mitchell, Jenny Han, Wenying Huang, Jaret Malloy, Christine Schulteis, Larry Shen and Lisa Porter

    Version of Record online : 15 MAR 2013, DOI: 10.1111/j.1365-2125.2012.04416.x

  5. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 6, June 2012, Pages: 546–554, M. S. Fineman, K. F. Mace, M. Diamant, T. Darsow, B. B. Cirincione, T. K. Booker Porter, L. A. Kinninger and M. E. Trautmann

    Version of Record online : 10 FEB 2012, DOI: 10.1111/j.1463-1326.2012.01561.x

  6. Once weekly exenatide: efficacy, tolerability and place in therapy

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 10, October 2013, Pages: 871–881, C. Wysham, M. Grimm and S. Chen

    Version of Record online : 24 MAR 2013, DOI: 10.1111/dom.12084

  7. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

    Diabetes/Metabolism Research and Reviews

    Volume 20, Issue 5, September/October 2004, Pages: 411–417, Mark S. Fineman, Larry Z. Shen, Kristin Taylor, Dennis D. Kim and Alain D. Baron

    Version of Record online : 28 JUL 2004, DOI: 10.1002/dmrr.499

  8. An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future

    Diabetes, Obesity and Metabolism

    Volume 13, Issue 5, May 2011, Pages: 394–407, S. Madsbad, U. Kielgast, M. Asmar, C. F. Deacon, S. S. Torekov and J. J. Holst

    Version of Record online : 24 MAR 2011, DOI: 10.1111/j.1463-1326.2011.01357.x

  9. You have full text access to this Open Access content
    Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

    Journal of Diabetes Investigation

    Volume 2, Issue 6, December 2011, Pages: 448–456, Nobuya Inagaki, Kohjiro Ueki, Ayuko Yamamura, Hitoshi Saito and Takeshi Imaoka

    Version of Record online : 26 JUN 2011, DOI: 10.1111/j.2040-1124.2011.00137.x

  10. You have full text access to this OnlineOpen article
    DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

    Diabetic Medicine

    Volume 28, Issue 6, June 2011, Pages: 705–714, C. Wysham, R. Bergenstal, J. Malloy, P. Yan, B. Walsh, J. Malone and K. Taylor

    Version of Record online : 16 MAY 2011, DOI: 10.1111/j.1464-5491.2011.03301.x

  11. You have full text access to this OnlineOpen article
    Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study

    Diabetes, Obesity and Metabolism

    Volume 19, Issue 7, July 2017, Pages: 979–988, Kishore M. Gadde, Marion L. Vetter, Nayyar Iqbal, Elise Hardy, Peter Öhman and on behalf of the DURATION-NEO-2 study investigators

    Version of Record online : 17 MAR 2017, DOI: 10.1111/dom.12908

    Corrected by:

    CORRIGENDUM: Corrigendum

    Vol. 19, Issue 9, 1332, Version of Record online: 23 AUG 2017

  12. Application of model-based methods to characterize exenatide-loaded double-walled microspheres: In vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 10, October 2012, Pages: 3946–3961, Xingang Li, Liang Li, Xipei Wang, Yupeng Ren, Tianyan Zhou and Wei Lu

    Version of Record online : 29 JUN 2012, DOI: 10.1002/jps.23236

  13. You have free access to this content
    Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity

    British Journal of Pharmacology

    Volume 163, Issue 2, May 2011, Pages: 399–412, Nian Gong, Ai-Niu Ma, Li-Jie Zhang, Xiao-Su Luo, Yin-Hui Zhang, Michael Xu and Yong-Xiang Wang

    Version of Record online : 18 APR 2011, DOI: 10.1111/j.1476-5381.2011.01227.x

  14. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

    International Journal of Clinical Practice

    Volume 64, Issue 10, September 2010, Pages: 1402–1414, D. Russell-Jones

    Version of Record online : 16 AUG 2010, DOI: 10.1111/j.1742-1241.2010.02465.x

  15. You have full text access to this OnlineOpen article
    Effect of renal impairment on the pharmacokinetics of exenatide

    British Journal of Clinical Pharmacology

    Volume 64, Issue 3, September 2007, Pages: 317–327, Helle Linnebjerg, Prajakti A. Kothare, Soomin Park, Kenneth Mace, Shobha Reddy, Malcolm Mitchell and Robert Lins

    Version of Record online : 10 APR 2007, DOI: 10.1111/j.1365-2125.2007.02890.x

  16. You have free access to this content
    Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 5, October 2012, Pages: 510–524, S. Cornell

    Version of Record online : 21 MAR 2012, DOI: 10.1111/j.1365-2710.2012.01342.x

  17. You have full text access to this Open Access content
    Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

    Journal of Diabetes Investigation

    Volume 2, Issue 3, June 2011, Pages: 210–217, Takashi Kadowaki, Mitsuyoshi Namba, Takeshi Imaoka, Ayuko Yamamura, Wakana Goto, Marilyn K. Boardman and Hideaki Sowa

    Version of Record online : 10 DEC 2010, DOI: 10.1111/j.2040-1124.2010.00084.x

  18. You have free access to this content
    Exenatide: a review from pharmacology to clinical practice

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 6, June 2009, Pages: 544–556, R. Gentilella, C. Bianchi, A. Rossi and C. M. Rotella

    Version of Record online : 5 APR 2009, DOI: 10.1111/j.1463-1326.2008.01018.x

  19. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

    Diabetes/Metabolism Research and Reviews

    Volume 27, Issue 6, September 2011, Pages: 528–542, Vanita R. Aroda and Robert Ratner

    Version of Record online : 7 SEP 2011, DOI: 10.1002/dmrr.1202

  20. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 5, May 2013, Pages: 417–426, K. Tatarkiewicz, P. Belanger, G. Gu, D. Parkes and D. Roy

    Version of Record online : 7 DEC 2012, DOI: 10.1111/dom.12040